Under microscope.

Congressional lawmakers in a hearing last week warned that they were considering a change in how the government reimburses doctors and dialysis centers for anemia treatment, a move that could hurt Thousand Oaks biotech giant Amgen Inc. Anemia drugs such as Amgen's Epogen are considered the single biggest medication expense for the federal Medicare program. The government now reimburses for dialysis services and drugs separately, which critics contend give doctors an incentive to prescribe higher doses to increase profits. Under consideration is a rule requiring dialysis centers to bill a single fee for dialysis treatment and drugs. Worldwide sales of Amgen's anemia line, which includes an extended-use version called Aranesp, are expected reach around $10 billion this year.